The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | A step towards next-generation immune monitoring in multiple myeloma?
Improved understanding of the tumor immune microenvironment (TIME) and its influence on response to therapy is needed. Here, Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, discusses the phenotypic, molecular and functional profiling of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the TIME of multiple myeloma (MM). This revealed three unique subsets of G-MDSCs and a number of optimal markers for monitoring them, with important potential implications. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
